200 related articles for article (PubMed ID: 29020849)
1. Microfluidic preparation of drug-loaded PEGylated liposomes, and the impact of liposome size on tumour retention and penetration.
Dong YD; Tchung E; Nowell C; Kaga S; Leong N; Mehta D; Kaminskas LM; Boyd BJ
J Liposome Res; 2019 Mar; 29(1):1-9. PubMed ID: 29020849
[TBL] [Abstract][Full Text] [Related]
2. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
[TBL] [Abstract][Full Text] [Related]
3. Rapid scale-up and production of active-loaded PEGylated liposomes.
Roces CB; Port EC; Daskalakis NN; Watts JA; Aylott JW; Halbert GW; Perrie Y
Int J Pharm; 2020 Aug; 586():119566. PubMed ID: 32622812
[TBL] [Abstract][Full Text] [Related]
4. Revealing Dynamics of Accumulation of Systemically Injected Liposomes in the Skin by Intravital Microscopy.
Griffin JI; Wang G; Smith WJ; Vu VP; Scheinman R; Stitch D; Moldovan R; Moghimi SM; Simberg D
ACS Nano; 2017 Nov; 11(11):11584-11593. PubMed ID: 29045127
[TBL] [Abstract][Full Text] [Related]
5. Cholesterol derivatives based charged liposomes for doxorubicin delivery: preparation, in vitro and in vivo characterization.
Nie Y; Ji L; Ding H; Xie L; Li L; He B; Wu Y; Gu Z
Theranostics; 2012; 2(11):1092-103. PubMed ID: 23227125
[TBL] [Abstract][Full Text] [Related]
6. A novel microfluidic-based approach to formulate size-tuneable large unilamellar cationic liposomes: Formulation, cellular uptake and biodistribution investigations.
Lou G; Anderluzzi G; Woods S; Roberts CW; Perrie Y
Eur J Pharm Biopharm; 2019 Oct; 143():51-60. PubMed ID: 31445156
[TBL] [Abstract][Full Text] [Related]
7. Derma roller® microneedles-mediated transdermal delivery of doxorubicin and celecoxib co-loaded liposomes for enhancing the anticancer effect.
Ahmed KS; Shan X; Mao J; Qiu L; Chen J
Mater Sci Eng C Mater Biol Appl; 2019 Jun; 99():1448-1458. PubMed ID: 30889679
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibody-targeted PEGylated liposome-ICG encapsulating doxorubicin as a potential theranostic agent.
Lozano N; Al-Ahmady ZS; Beziere NS; Ntziachristos V; Kostarelos K
Int J Pharm; 2015 Mar; 482(1-2):2-10. PubMed ID: 25445515
[TBL] [Abstract][Full Text] [Related]
9. Comparative plasma and tissue distribution of Sun Pharma's generic doxorubicin HCl liposome injection versus Caelyx
Burade V; Bhowmick S; Maiti K; Zalawadia R; Jain D; Rajamannar T
Cancer Chemother Pharmacol; 2017 May; 79(5):899-913. PubMed ID: 28349166
[TBL] [Abstract][Full Text] [Related]
10. A Microfluidic Platform for Evaluating the Internalization of Liposome Drug Carriers in Tumor Spheroids.
Yakavets I; Ayachit M; Kheiri S; Chen Z; Rakhshani F; McWhirter S; Young EWK; Walker GC; Kumacheva E
ACS Appl Mater Interfaces; 2024 Feb; 16(8):9690-9701. PubMed ID: 38357740
[TBL] [Abstract][Full Text] [Related]
11. Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect.
Xie Q; Deng W; Yuan X; Wang H; Ma Z; Wu B; Zhang X
Eur J Pharm Biopharm; 2018 Jan; 122():87-95. PubMed ID: 29032193
[TBL] [Abstract][Full Text] [Related]
12. Microfluidic preparation of liposomes to determine particle size influence on cellular uptake mechanisms.
Andar AU; Hood RR; Vreeland WN; Devoe DL; Swaan PW
Pharm Res; 2014 Feb; 31(2):401-13. PubMed ID: 24092051
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of polydopamine modified and conventional chemical synthesis method in doxorubicin liposomes form the aspect of tumor targeted therapy.
Bi D; Zhao L; Li H; Guo Y; Wang X; Han M
Int J Pharm; 2019 Mar; 559():76-85. PubMed ID: 30677481
[TBL] [Abstract][Full Text] [Related]
14. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
Charrois GJ; Allen TM
Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
[TBL] [Abstract][Full Text] [Related]
15. Sterically stabilized liposomes production using staggered herringbone micromixer: Effect of lipid composition and PEG-lipid content.
Cheung CCL; Al-Jamal WT
Int J Pharm; 2019 Jul; 566():687-696. PubMed ID: 31212051
[TBL] [Abstract][Full Text] [Related]
16. Dual-effect liposomes encapsulated with doxorubicin and chlorin e6 augment the therapeutic effect of tumor treatment.
Peng PC; Hong RL; Tsai YJ; Li PT; Tsai T; Chen CT
Lasers Surg Med; 2015 Jan; 47(1):77-87. PubMed ID: 25559348
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin-loaded nanocarriers: A comparative study of liposome and nanostructured lipid carrier as alternatives for cancer therapy.
Fernandes RS; Silva JO; Monteiro LOF; Leite EA; Cassali GD; Rubello D; Cardoso VN; Ferreira LAM; Oliveira MC; de Barros ALB
Biomed Pharmacother; 2016 Dec; 84():252-257. PubMed ID: 27664949
[TBL] [Abstract][Full Text] [Related]
18. Co-Delivery of Hispolon and Doxorubicin Liposomes Improves Efficacy Against Melanoma Cells.
Al Saqr A; Aldawsari MF; Alrbyawi H; Poudel I; Annaji M; Mulabagal V; Ramani MV; Gottumukkala S; Tiwari AK; Dhanasekaran M; Panizzi PR; Arnold RD; Babu RJ
AAPS PharmSciTech; 2020 Nov; 21(8):304. PubMed ID: 33150503
[TBL] [Abstract][Full Text] [Related]
19. The application of EDTA in drug delivery systems: doxorubicin liposomes loaded via NH4EDTA gradient.
Song Y; Huang Z; Song Y; Tian Q; Liu X; She Z; Jiao J; Lu E; Deng Y
Int J Nanomedicine; 2014; 9():3611-21. PubMed ID: 25120359
[TBL] [Abstract][Full Text] [Related]
20. Microfluidic directed formation of liposomes of controlled size.
Jahn A; Vreeland WN; DeVoe DL; Locascio LE; Gaitan M
Langmuir; 2007 May; 23(11):6289-93. PubMed ID: 17451256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
